SignificanceQuantitative phase imaging (QPI) offers a label-free approach to non-invasively characterize cellular processes by exploiting their refractive index based intrinsic contrast. QPI captures this contrast by translating refractive index associated phase shifts into intensity-based quantifiable data with nanoscale sensitivity. It holds significant potential for advancing precision cancer medicine by providing quantitative characterization of the biophysical properties of cells and tissue in their natural states.AimThis perspective aims to discuss the potential of QPI to increase our understanding of cancer development and its response to therapeutics. It also explores new developments in QPI methods towards advancing personalized cancer therapy and early detection.ApproachWe begin by detailing the technical advancements of QPI, examining its implementations across transmission and reflection geometries and phase retrieval methods, both interferometric and non-interferometric. The focus then shifts to QPI’s applications in cancer research, including dynamic cell mass imaging for drug response assessment, cancer risk stratification, and in-vivo tissue imaging.ResultsQPI has emerged as a crucial tool in precision cancer medicine, offering insights into tumor biology and treatment efficacy. Its sensitivity to detecting nanoscale changes holds promise for enhancing cancer diagnostics, risk assessment, and prognostication. The future of QPI is envisioned in its integration with artificial intelligence, morpho-dynamics, and spatial biology, broadening its impact in cancer research.ConclusionsQPI presents significant potential in advancing precision cancer medicine and redefining our approach to cancer diagnosis, monitoring, and treatment. Future directions include harnessing high-throughput dynamic imaging, 3D QPI for realistic tumor models, and combining artificial intelligence with multi-omics data to extend QPI’s capabilities. As a result, QPI stands at the forefront of cancer research and clinical application in cancer care.
Nanoscale nuclear architecture mapping (nanoNAM) is a label free imaging method based on the Fourier phase of Fourier-domain optical coherence tomography. It is capable of capturing, with nanoscale sensitivity, preneoplastic alterations in nuclear architecture of normal appearing cells undergoing malignant transformation both in animal models of carcinogenesis and human patients. In this talk I will present its theory and implementation from first principles and demonstrate its utility in a range of cancer settings. I will further present our recent results on testing the hypothesis that the ability of nanoNAM to capture early-stage malignant transformation is due to its sensitivity to the underlying aberrant structural alterations associated with chromatin remodeling during early stages of carcinogenesis. I will conclude by discussing its potential for use in the clinic.
Malignant transformation of normal epithelial cells involves extensive epigenetic reprogramming that alters the structure of chromatin within the cell nuclei. We have shown that Fourier phase associated with nanoscale nuclear architecture mapping (nanoNAM) of epithelial cells based on Fourier-domain optical coherence tomography (FD-OCT) can capture the resulting changes in nuclear architecture via nanoscale-sensitive joint characterization of coherence-gated mean alteration in nuclear refractive index and its associated heterogeneity. Here, using computational modeling and stochastic optical reconstruction microscopy (STORM) based super-resolution imaging, we demonstrate the underlying structural changes of chromatin remodeling during malignant transformation in epithelial cells measured by depth-resolved nanoNAM.
One of the greatest challenges for early cancer detection is how to effectively manage patients who are at risk for developing invasive cancer. As most at-risk patients will not develop cancer, frequent and invasive surveillance of atrisk patients carries financial, physical, and emotional burdens. But clinicians lack tools to accurately predict which patients will likely progress into malignancy. With our increased understanding of molecular changes in cancer development, it is now established that disrupted epigenome that can alter nuclear architecture occurs in all stages of cancer development including in normal precursor cells. Therefore, assessment of nanoscale nuclear architecture represents a promising strategy for identifying pre-cancerous changes. Here we present the development of threedimensional nuclear architecture mapping (3D-nanoNAM) to assess the depth-resolved properties of phase objects with slowly varying refractive index without a strong interface, based on a variant form of Fourier-domain optical coherence tomography (FD-OCT). By computing the Fourier phase of the FD-OCT signal resulting from the light back-scattered by cell nuclei, 3D-nanoNAM quantifies, with nanoscale sensitivity, the depth-resolved alterations in mean nuclear optical density, and localized heterogeneity in optical density of the cell nuclei. We demonstrate that 3D-nanoNAM distinguishes high-risk patients with inflammatory bowel disease (IBD) colitis from those at low-risk via/through imaging tissue sections that appear histologically normal according to pathologists. As 3D-nanoNAM uses clinically prepared formalin-fixed, paraffin-embedded tissue sections, it can be integrated into the clinical workflow.
Pathology remains the gold standard for cancer diagnosis and in some cases prognosis, in which trained pathologists examine abnormality in tissue architecture and cell morphology characteristic of cancer cells with a bright-field microscope. The limited resolution of conventional microscope can result in intra-observer variation, missed early-stage cancers, and indeterminate cases that often result in unnecessary invasive procedures in the absence of cancer. Assessment of nanoscale structural characteristics via quantitative phase represents a promising strategy for identifying pre-cancerous or cancerous cells, due to its nanoscale sensitivity to optical path length, simple sample preparation (i.e., label-free) and low cost. I will present the development of quantitative phase microscopy system in transmission and reflection configuration to detect the structural changes in nuclear architecture, not be easily identifiable by conventional pathology. Specifically, we will present the use of transmission-mode quantitative phase imaging to improve diagnostic accuracy of urine cytology and the nuclear dry mass is progressively correlate with negative, atypical, suspicious and positive cytological diagnosis. In a second application, we will present the use of reflection-mode quantitative phase microscopy for depth-resolved nanoscale nuclear architecture mapping (nanoNAM) of clinically prepared formalin-fixed, paraffin-embedded tissue sections. We demonstrated that the quantitative phase microscopy system detects a gradual increase in the density alteration of nuclear architecture during malignant transformation in animal models of colon carcinogenesis and in human patients with ulcerative colitis, even in tissue that appears histologically normal according to pathologists. We evaluated the ability of nanoNAM to predict "future" cancer progression in patients with ulcerative colitis.
Fourier phase in Fourier-domain optical coherence tomography (FD-OCT) has been shown to estimate the sub-
resolution change in the optical depth location of a strong interface in refractive index profile of a sample using
spectral-domain phase microscopy (SDPM), a derivative of FD-OCT. From first principles we show that in
general Fourier phase not only estimates this sub-resolution change but also the mean spatial frequency of the
coherence-gated refractive index, and both SDPM and depth-resolved spatial-domain low-coherence quantitative
phase microscopy (dr-SLQPM) are special cases of this general theory. We also show that for spectral source
with infinite bandwidth Fourier phase is zero. We provide analytical expressions and numerical simulations to
support our results.
Effective management of patients who are at risk of developing invasive cancer is a primary challenge in early cancer
detection. Techniques that can help establish clear-cut protocols for successful triaging of at-risk patients have the
potential of providing critical help in improving patient care while simultaneously reducing patient cost. We have
developed such a technique for early prediction of cancer progression that uses unstained tissue sections to provide
depth-resolved nanoscale nuclear architecture mapping (nanoNAM) of heterogeneity in optical density alterations
manifested in precancerous lesions during cancer progression. We present nanoNAM and its application to predicting
cancer progression in a well-established mouse model of spontaneous carcinogenesis: ApcMin/+ mice.
The development of accurate and clinically applicable tools to assess cancer risk is essential to define candidates to undergo screening for early-stage cancers at a curable stage or provide a novel method to monitor chemoprevention treatments. With the use of our recently developed optical technology—spatial-domain low-coherence quantitative phase microscopy (SL-QPM), we have derived a novel optical biomarker characterized by structure-derived optical path length (OPL) properties from the cell nucleus on the standard histology and cytology specimens, which quantifies the nano-structural alterations within the cell nucleus at the nanoscale sensitivity, referred to as nano-morphology marker. The aim of this study is to evaluate the feasibility of the nuclear nano-morphology marker from histologically normal cells, extracted directly from the standard histology specimens, to detect early-stage carcinogenesis, assess cancer risk, and monitor the effect of chemopreventive treatment. We used a well-established mouse model of spontaneous carcinogenesis—ApcMin mice, which develop multiple intestinal adenomas (Min) due to a germline mutation in the adenomatous polyposis coli (Apc) gene. We found that the nuclear nano-morphology marker quantified by OPL detects the development of carcinogenesis from histologically normal intestinal epithelial cells, even at an early pre-adenomatous stage (six weeks). It also exhibits a good temporal correlation with the small intestine that parallels the development of carcinogenesis and cancer risk. To further assess its ability to monitor the efficacy of chemopreventive agents, we used an established chemopreventive agent, sulindac. The nuclear nano-morphology marker is reversed toward normal after a prolonged treatment. Therefore, our proof-of-concept study establishes the feasibility of the SL-QPM derived nuclear nano-morphology marker OPL as a promising, simple and clinically applicable biomarker for cancer risk assessment and evaluation of chemopreventive treatment.
For any technique to be adopted into a clinical setting, it is imperative that it seamlessly integrates with well-established clinical diagnostic workflow. We recently developed an optical microscopy technique-spatial-domain low-coherence quantitative phase microscopy (SL-QPM) that can extract the refractive index of the cell nucleus from the standard histology specimens on glass slides prepared via standard clinical protocols. This technique has shown great potential in detecting cancer with a better sensitivity than conventional pathology. A major hurdle in the clinical translation of this technique is the intrinsic variation among staining agents used in histology specimens, which limits the accuracy of refractive index measurements of clinical samples. In this paper, we present a simple and easily generalizable method to remove the effect of variations in staining levels on nuclear refractive index obtained with SL-QPM. We illustrate the efficacy of our correction method by applying it to variously stained histology samples from animal model and clinical specimens.
Intrigued by our recent finding that the nuclear refractive index is significantly increased in malignant cells and histologically normal cells in clinical histology specimens derived from cancer patients, we sought to identify potential biological mechanisms underlying the observed phenomena. The cell cycle is an ordered series of events that describes the intervals of cell growth, DNA replication, and mitosis that precede cell division. Since abnormal cell cycles and increased proliferation are characteristic of many human cancer cells, we hypothesized that the observed increase in nuclear refractive index could be related to an abundance or accumulation of cells derived from cancer patients at a specific point or phase(s) of the cell cycle. Here we show that changes in nuclear refractive index of fixed cells are seen as synchronized populations of cells that proceed through the cell cycle, and that increased nuclear refractive index is strongly correlated with increased DNA content. We therefore propose that an abundance of cells undergoing DNA replication and mitosis may explain the increase in nuclear refractive index observed in both malignant and histologically normal cells from cancer patients. Our findings suggest that nuclear refractive index may be a novel physical parameter for early cancer detection and risk stratification.
Definitive diagnosis of malignancy is often challenging due to limited availability of human cell or tissue samples and morphological similarity with certain benign conditions. Our recently developed novel technology-spatial-domain low-coherence quantitative phase microscopy (SL-QPM)-overcomes the technical difficulties and enables us to obtain quantitative information about cell nuclear architectural characteristics with nanoscale sensitivity. We explore its ability to improve the identification of malignancy, especially in cytopathologically non-cancerous-appearing cells. We perform proof-of-concept experiments with an animal model of colorectal carcinogenesis-APCMin mouse model and human cytology specimens of colorectal cancer. We show the ability of in situ nanoscale nuclear architectural characteristics in identifying cancerous cells, especially in those labeled as "indeterminate or normal" by expert cytopathologists. Our approach is based on the quantitative analysis of the cell nucleus on the original cytology slides without additional processing, which can be readily applied in a conventional clinical setting. Our simple and practical optical microscopy technique may lead to the development of novel methods for early detection of cancer.
We consider direct minimum mean-squared error (MMSE) reconstruction of difference images without explicit
reconstruction of the two images at the two time instants. We first derive the MMSE reconstruction operator
and show that it depends on the cross-correlation between the two images taken at different times. We then
consider the reconstruction performance of different strategies for measuring linear spatial projections of the two
images. Performance is evaluated by using measured video imagery of an urban intersection as the input into a
simulation that models the linear projections.
We describe a novel method to track targets in a large field of view. This method simultaneously images multiple,
encoded sub-fields of view onto a common focal plane. Sub-field encoding enables target tracking by creating
a unique connection between target characteristics in superposition space and the target's true position in real
space. This is accomplished without reconstructing a conventional image of the large field of view. Potential
encoding schemes include spatial shift, rotation, and magnification. We briefly discuss each of these encoding
schemes, but the main emphasis of the paper and all examples are based on one-dimensional spatial shift encoding.
Simulation results are included to show the efficacy of the proposed sub-field encoding scheme.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.